Look back at pharma news in the week to September 3, 2021
Significant clinical trial news last week included AC Immune and Roche subsidiary Genentech reporting encouraging Phase II data on their Alzheimer’s disease candidate semorinemab, while Japan’s Takeda presented Phase III results for its myeloid leukemia hopeful pevonedistat that failed to meet study endpoints. Among regulatory news, Chinese biotech BeiGene received a second US Food and Drug Administration approval for Brukinsa, this time for the treatment of Waldenström’s macroglobulinemia. Also, the FDA finally released its much-anticipated review of JAK inhibitors, with damaging warnings on the safety of drugs, such as Pfizer’s Xeljanz, AbbVie’s Rinvoq and Eli Lilly’s Olumiant.
AC Immune claims a tau win in Alzheimer’s
These days mixed data in Alzheimer’s disease are enough to send a company’s stock rocketing. Monday, AC Immune was the beneficiary after claiming a win in the Phase II LAURIET trial of its tau-targeting agent semorinemab, commented Madeleine Armstrong writing on Evaluate Vantage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze